"10.1371_journal.pone.0090453","plos one","2014-11-04T00:00:00Z","Antoni Sicras-Mainar; Pablo Guijarro; Beatriz Armada; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda","Directorate of Planning, Badalona Serveis Assistencials, S.A., Badalona, Barcelona, Spain; Pfizer, Madrid, Spain; Department of Psychiatry, Badalona Serveis Assistencials, S.A., Badalona, Barcelona, Spain; Medical Documentation, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain","Conceived and designed the experiments: ASM RNA PG BA. Performed the experiments: ASM. Analyzed the data: ASM. Contributed reagents/materials/analysis tools: ASM. Wrote the paper: ASM. Authorship and manuscript review: ASM PG BA MBT RNA. Final approval of manuscript: ASM PG BA MBT RNA.","This study was funded by Pfizer Inc. P. Guijarro and B. Armada are full-time employees of Pfizer, SLU. A. Sicras-Mainar was paid as a consultant from Pfizer, responsible for data collection and analysis and statistical analysis. Venlafaxine is a Pfizer product. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","11","Antoni Sicras-Mainar","ASM",5,TRUE,4,1,1,1,TRUE,TRUE,FALSE,0,NA,FALSE
